

Cancer Therapy Related Diarrhea – Pipeline Insight, 2020

<https://marketpublishers.com/r/C7ADA1B42D03EN.html>

Date: November 2020

Pages: 40

Price: US\$ 1,500.00 (Single User License)

ID: C7ADA1B42D03EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Cancer Therapy Related Diarrhea – Pipeline Insight, 2020," report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Cancer Therapy Related Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Cancer Therapy Related Diarrhea Understanding

Cancer Therapy Related Diarrhea: Overview

Cancer Therapy Related Diarrhea is a common problem, especially in patients with advanced cancer. It is one of the main drawbacks for cancer patients. In oncological patients, diarrhea can occur in several different situations. Possible causes could be radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host disease and infections and has to be carefully differentiated from other causes of diarrhea. Cancer therapy related diarrhea can cause depletion of fluids and electrolytes, malnutrition, dehydration and hospitalization, all of which can lead to cardiovascular compromise and death. In addition, diarrhea can interfere with and detract from cancer

treatment by causing dosing delays or reductions which may have an impact on survival.

Symptoms

The symptoms of Cancer Therapy Related Diarrhea include:

Dehydration

Dizzy or light headed

Fever

Dark yellow urine or not urinating

Diagnosis

Diagnosis of Cancer Therapy Related Diarrhea begins with a history to determine the severity according to the National Cancer Institute Common Toxicity grades. The volume and duration of diarrhea should also be determined, and the history should include questions concerning foods or drugs that might play a contributory role.

Treatment

The treatment of CID includes nonpharmacologic and pharmacologic interventions to control diarrhea and careful serial evaluation to rule out significant volume depletion or comorbidities that would require specific intervention or hospitalization. Initial nonpharmacologic measures include avoidance of foods that would aggravate the diarrhea and aggressive oral rehydration with fluids that contain water, salt, and sugar. loperamide, octreotide and tincture of opium are recommended in the updated treatment guidelines by the consensus conference on the management of Cancer Therapy Related Diarrhea.

Cancer Therapy Related Diarrhea Emerging Drugs Chapters

This segment of the Cancer Therapy Related Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive

pharmacological action, agreements and collaborations, and the latest news and press releases.

Cancer Therapy Related Diarrhea Emerging Drugs

Crofelemer: Napo Pharmaceuticals

Crofelemer is a drug that is a chloride channel antagonist and is presently being studied in Phase III of clinical trial. Originally, this compound was owned by Shaman Pharmaceuticals and currently under the development of Napo Pharmaceuticals.

Further product details are provided in the report

Cancer Therapy Related Diarrhea: Therapeutic Assessment

This segment of the report provides insights about the different Cancer Therapy Related Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cancer Therapy Related Diarrhea

There are approx. 2+ key companies which are developing the therapies for Cancer Therapy Related Diarrhea. The companies which have their Cancer Therapy Related Diarrhea drug candidates in the most advanced stage, i.e. phase III include, Napo Pharmaceuticals.

Phases

DelveInsight's report covers around 2+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cancer Therapy Related Diarrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cancer Therapy Related Diarrhea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Therapy Related Diarrhea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Therapy Related Diarrhea drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cancer Therapy Related Diarrhea R&D. The therapies under development are focused on novel approaches to treat/improve Cancer Therapy Related Diarrhea.

Cancer Therapy Related Diarrhea Report Insights

Cancer Therapy Related Diarrhea Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Cancer Therapy Related Diarrhea Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Cancer Therapy Related Diarrhea drugs?

How many Cancer Therapy Related Diarrhea drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cancer Therapy Related Diarrhea?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cancer Therapy Related Diarrhea therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cancer Therapy Related Diarrhea and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Napo Pharmaceuticals

Key Products

Crofelemer

Contents

Introduction

Executive Summary

Cancer Therapy Related Diarrhea: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Cancer Therapy Related Diarrhea – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Cancer Therapy Related Diarrhea companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Cancer Therapy Related Diarrhea Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Crofelemer: Napo Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Cancer Therapy Related Diarrhea Key Companies

Cancer Therapy Related Diarrhea Key Products

Cancer Therapy Related Diarrhea- Unmet Needs

Cancer Therapy Related Diarrhea- Market Drivers and Barriers

Cancer Therapy Related Diarrhea- Future Perspectives and Conclusion

Cancer Therapy Related Diarrhea Analyst Views

Cancer Therapy Related Diarrhea Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Cancer Therapy Related Diarrhea

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Cancer Therapy Related Diarrhea

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Cancer Therapy Related Diarrhea – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/C7ADA1B42D03EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C7ADA1B42D03EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970